Literature DB >> 15148555

Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma.

Jos A M Bramer1, Feikje M Gubler, Mario Maas, Hans Bras, Jan de Kraker, Jan W van der Eijken, Gerard R Schaap.   

Abstract

BACKGROUND: Histological response to chemotherapy is an important prognostic factor in osteosarcoma, influencing therapeutic considerations. It would be advantageous to be able to assess chemotherapy response, and predict survival, prior to tumour resection. Colour Doppler US (CDUS) is non-invasive, non-demanding for the patient, and easy to plan. This makes the method especially suitable for children, who comprise the majority of patients.
OBJECTIVE: To establish the value of CDUS for pre-operative prediction of chemotherapy response and survival, using widely available US equipment.
MATERIALS AND METHODS: CDUS was performed in 21 consecutive patients before and after chemotherapy. Peak systolic velocity (PSV) in the soft-tissue component of the tumour and quotient of resistive index (QRI) of the feeding artery and contralateral control were calculated. A pathologist, unaware of CDUS results, assessed the response to chemotherapy after resection.
RESULTS: QRI change after chemotherapy was significantly higher in histological responders. No correlation of QRI change with survival was found. There was no significant difference in PSV change comparing any subgroup. CDUS appeared useful in predicting chemotherapy response (sensitivity 83%, specificity 86%), especially for negative response (predictive value 92%). Survival could not be predicted accurately.
CONCLUSIONS: CDUS can predict chemotherapy response, but not survival. The method could be useful in planning treatment prior to definitive surgery.

Entities:  

Mesh:

Year:  2004        PMID: 15148555     DOI: 10.1007/s00247-004-1210-z

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  26 in total

1.  Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy.

Authors:  P Ongolo-Zogo; P Thiesse; J Sau; C Desuzinges; J Y Blay; A Bonmartin; M Bochu; T Philip
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

Review 2.  Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation.

Authors:  B D Fletcher
Journal:  AJR Am J Roentgenol       Date:  1991-10       Impact factor: 3.959

3.  Technetium-99m tetrofosmin scintigraphy in pediatric osteogenic sarcoma.

Authors:  Orazio Schillaci; Angela Spanu; Francesco Scopinaro; Francesco Monteleone; Salvatore Masala; Umberto Tarantino; Giuseppe Madeddu; Giovanni Simonetti
Journal:  Oncol Rep       Date:  2003 May-Jun       Impact factor: 3.906

4.  Rotation-plasty.

Authors:  J A Fixsen
Journal:  J Bone Joint Surg Br       Date:  1983-11

Review 5.  Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities.

Authors:  H J van der Woude; J L Bloem; P C Hogendoorn
Journal:  Skeletal Radiol       Date:  1998-02       Impact factor: 2.199

6.  Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.

Authors:  Douglas S Hawkins; Joseph G Rajendran; Ernest U Conrad; James D Bruckner; Janet F Eary
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

Review 7.  Prognostic factors in osteosarcoma: a critical review.

Authors:  A M Davis; R S Bell; P J Goodwin
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

8.  Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response.

Authors:  H J van der Woude; J L Bloem; J A van Oostayen; M A Nooy; A H Taminiau; J Hermans; M Reynierse; P C Hogendoorn
Journal:  AJR Am J Roentgenol       Date:  1995-07       Impact factor: 3.959

9.  Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography.

Authors:  P Lang; M Vahlensieck; K K Matthay; J O Johnston; W Rosenau; C A Gooding; H K Genant
Journal:  Med Pediatr Oncol       Date:  1996-05

10.  Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging.

Authors:  Jonathan P Dyke; David M Panicek; John H Healey; Paul A Meyers; Andrew G Huvos; Lawrence H Schwartz; Howard T Thaler; Paul S Tofts; Richard Gorlick; Jason A Koutcher; Douglas Ballon
Journal:  Radiology       Date:  2003-07       Impact factor: 11.105

View more
  4 in total

1.  Differential diagnosis between benign and malignant soft tissue tumors utilizing ultrasound parameters.

Authors:  Takeshi Morii; Tomonori Kishino; Naoko Shimamori; Mitsue Motohashi; Hiroaki Ohnishi; Keita Honya; Takayuki Aoyagi; Takashi Tajima; Shoichi Ichimura
Journal:  J Med Ultrason (2001)       Date:  2017-06-20       Impact factor: 1.314

2.  Gray-scale and color Doppler ultrasonographic evaluation of reactivated post-traumatic/postoperative chronic osteomyelitis.

Authors:  A P Balanika; O Papakonstantinou; C J Kontopoulou; C S Baltas; S Athanassia; K Kanelakopoulou; E Brountzos; A Gouliamos; N L Kelekis
Journal:  Skeletal Radiol       Date:  2008-12-10       Impact factor: 2.199

3.  Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts.

Authors:  Jian-Wei Wang; Wei Zheng; Ji-Bin Liu; Yao Chen; Long-Hui Cao; Rong-Zhen Luo; An-Hua Li; Jian-Hua Zhou
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

4.  Preoperative Ultrasonographic Evaluation for Malignancy of Soft-Tissue Sarcoma: A Retrospective Study.

Authors:  Takeshi Morii; Tomonori Kishino; Naoko Shimamori; Mitsue Motohashi; Hiroaki Ohnishi; Keita Honya; Takayuki Aoyagi; Takashi Tajima; Shoichi Ichimura
Journal:  Open Orthop J       Date:  2018-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.